Kato Kengo, Shimazaki Kuniko, Kamiya Tatsushi, Amemiya Shimon, Inaba Toshiki, Oguro Keiji, Katayama Yasuo
The Second Department of Internal Medicine, Nippon Medical School, 1-1-5 Bunkyo-ku, Sendagi, Tokyo, 113-8603, Japan.
Life Sci. 2005 Oct 21;77(23):2867-78. doi: 10.1016/j.lfs.2005.01.037. Epub 2005 Jun 14.
Pretreatment with a low dose of 3-nitropropionic acid (3-NPA) has been shown to induce ischemic tolerance in the gerbil hippocampus. It is well known that sublethal (2-min) ischemia also induces ischemic tolerance. To investigate the acquisition of ischemic tolerance with 3-NPA, we examined the protein expression after 3-NPA treatment in comparison with sublethal ischemia. Immunohistochemical studies revealed intense expression of Bcl-2 and Bcl-xL in the hippocampal CA1 area after 3-NPA treatment. Furthermore, the time course of the expression of Bcl-xL showed a similar pattern to the acquisition of ischemic tolerance by 3-NPA treatment. The induction of Bcl-xL occurred in the hippocampal CA1 area at 24 h after 3-NPA treatment, and significant induction was observed at 48 h. Western blot analysis of hippocampus harvested 48 h after the pretreatment, showed that the expression of Bcl-2 and Bcl-xL was significantly increased by either 3-NPA treatment or 2-min ischemia. However, PMCA1 and HSP70 protein expression increased only in the sublethal ischemia treated group. The difference between 3-NPA treated group and control group was not statistically significant. These results suggest that Bcl-2 and Bcl-xL are essential for acquisition of ischemic tolerance, while HSP70 and PMCA1 play important roles in the enhancement of ischemic tolerance.
低剂量3-硝基丙酸(3-NPA)预处理已被证明可诱导沙鼠海马体产生缺血耐受。众所周知,亚致死性(2分钟)缺血也可诱导缺血耐受。为了研究3-NPA诱导缺血耐受的机制,我们将3-NPA处理后的蛋白表达与亚致死性缺血进行了比较。免疫组织化学研究显示,3-NPA处理后海马CA1区Bcl-2和Bcl-xL表达增强。此外,Bcl-xL表达的时间进程与3-NPA处理诱导缺血耐受的模式相似。Bcl-xL的诱导在3-NPA处理后24小时出现在海马CA1区,48小时观察到显著诱导。对预处理48小时后采集的海马进行蛋白质印迹分析表明,3-NPA处理或2分钟缺血均可显著增加Bcl-2和Bcl-xL的表达。然而,PMCA1和HSP7蛋白表达仅在亚致死性缺血处理组中增加。3-NPA处理组与对照组之间的差异无统计学意义。这些结果表明,Bcl-2和Bcl-xL对缺血耐受的获得至关重要,而HSP70和PMCA1在增强缺血耐受中起重要作用。